This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: anticoagulant

Treatment of VTE in primary care: building a new approach to patient management with rivaroxaban

June 2015 Br J Cardiol 2015;22:78 doi:10.5837/bjc.2015.021

Treatment of VTE in primary care: building a new approach to patient management with rivaroxaban

Rosie Heath

Abstract

Introduction Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), causes considerable morbidity and mortality.1 VTE is associated with 370,000 deaths per year in the European Union (EU), an estimated 12% of annual deaths.1 The average incidence of VTE in Europe is approximately 160–180 per 100,000 person-years.1 Three large phase III trials with rivaroxaban, a direct factor Xa inhibitor approved for the treatment and prevention of VTE, have provided a strong safety and efficacy evidence base (table 1). The EINSTEIN-DVT study compared rivaroxaban (15 mg twice daily for 21 days, followed by 20 mg on

| Full text
News from the American Heart Association Scientific Sessions 2013

February 2014 Br J Cardiol 2014;21:10–11 Online First

News from the American Heart Association Scientific Sessions 2013

BJCardio Staff

Abstract

ENGAGE AF-TIMI 48: success for edoxaban in AF The new factor Xa inhibitor, edoxaban (Daiichi-Sankyo), was as effective in preventing strokes and safer than warfarin in patients with atrial fibrillation (AF) in the ENGAGE AF-TIMI 48 trial. The ENGAGE AF-TIMI 48 (Effective AnticoaGulation with Factor XA Next Generation in Atrial Fibrillation – Thrombolysis In Myocardial Infarction 48) trial included more than 21,000 AF patients from 46 countries who were randomised to edoxaban at one of two doses (60 mg or 30 mg per day) or warfarin. Results (table 1) showed that both edoxaban doses were associated with significantly less major bleeding than

| Full text

March 2008 Br J Cardiol 2008;15:87-94

New anticoagulant strategies in ST-elevation myocardial infarction treated with fibrinolytic therapy

Ian B A Menown

Abstract

Introduction Culprit artery reperfusion with fibrinolytic therapy and/or percutaneous coronary intervention (PCI) is the established treatment for ST-elevation myocardial infarction (STEMI), with rapid access to optimised treatment providing the best outcome.1,2 Although timely primary PCI compared with fibrinolytic therapy for STEMI has demonstrated potential benefits in mortality and morbidity1 and pilot primary PCI services are currently being evaluated around the UK, fibrinolytic therapy remains the most common form of reperfusion treatment. An area of ongoing research is the optimisation of adjuvant treatment, in particular the anticoagu

| Full text

November 2004 Br J Cardiol (Acute Interv Cardiol) 2004;11:AIC 85–AIC 88

Bivalirudin in percutaneous coronary intervention

Daniel J Blackman, Adrian P Banning

Abstract

No content available

| Full text

June 2002 Br J Cardiol 2002;9:356-7

Serious interaction between digoxin and warfarin

Arpandev Bhattacharyya, Manju Bhavnani, David James Tymms

Abstract

(more…)

| Full text

For healthcare professionals only

Add Banner

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now